

Other version: http://www.sciencedirect.com/science/article/pii/S0140673600020341#
![]() |
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial |
|
Authors | ![]() | |
Published in | The Lancet. 2000, vol. 355, no. 9209, p. 1041-7 | |
Abstract | Irinotecan is active against colorectal cancer in patients whose disease is refractory to fluorouracil. We investigated the efficacy of these two agents combined for first-line treatment of metastatic colorectal cancer. | |
Keywords | Adenocarcinoma/drug therapy/mortality/pathology — Adult — Aged — Antineoplastic Agents, Phytogenic/administration & dosage/adverse effects — Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use — Camptothecin/administration & dosage/adverse effects/analogs & derivatives — Colorectal Neoplasms/drug therapy/mortality/pathology — Female — Fluorouracil/administration & dosage/adverse effects — Humans — Leucovorin/administration & dosage/adverse effects — Male — Middle Aged — Neoplasm Staging — Quality of Life — Survival Rate | |
Identifiers | PMID: 10744089 | |
Full text |
![]() ![]() Other version: http://www.sciencedirect.com/science/article/pii/S0140673600020341# |
|
Structures | ||
Research group | Groupe Roth Arnaud (oncologie) (285) | |
Citation (ISO format) | DOUILLARD, J Y et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. In: The Lancet, 2000, vol. 355, n° 9209, p. 1041-7. https://archive-ouverte.unige.ch/unige:55094 |